Scarica l'app Stockscreener
262.82
1.11%
2.89
Dopo l'orario di chiusura:
263.04
0.22
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Hig - GuruFocus
AbbVie long-term data buoys Rinvoq for vitiligo - Seeking Alpha
AbbVie Presents Long-Term RINVOQ® Data Showing Continued Repigmentation in Non-Segmental Vitiligo - Investing News Network
Why Is AbbVie (NYSE:ABBV) Suddenly a Must-Watch Healthcare Stocks Stock Today? - kalkinemedia.com
AbbVie to Host Third-Quarter 2026 Earnings Conference Call - Investing News Network
AbbVie to release Q3 2026 earnings on Oct 30 be... - Pluang
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - uk.finance.yahoo.com
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? - Zacks Investment Research
AbbVie stock pre-market at EUR 231.40: minus 0.09 percent - AD HOC NEWS
New report explores the future of aesthetic treatments - kutv.com
AbbVie Stock: Buy, Sell, or Hold in October? - theglobeandmail.com
AbbVie’s eczema drug shows benefit in Phase 2; BioMarin lays off 117 - Endpoints News
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates - Benzinga
AbbVie unveils promising results for its obesity drug candidate - marketscreener.com
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength - AOL.com
AbbVie (ABBV) Reports Promising Phase 1 Weight Loss Data for ABB - GuruFocus
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE) - Seeking Alpha
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 - Investing News Network
AbbVie's Zumilokibart Phase 2 Success Highlights Dividend Sustai - GuruFocus
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress - Investing News Network
At 16 weeks, all three doses of AbbVie’s eczema treatment improved skin more than placebo. - Stock Titan
AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis - Seeking Alpha
Three late-breaking reports will be part of AbbVie's 60 research presentations on skin diseases. - Stock Titan
AbbVie Inc (ABBV) Stock Down 1.1% but Still Overvalued -- GF Sco - GuruFocus
Enterprise value of AbbVie, Inc. – HAN:4AB - TradingView
If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - Benzinga
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo! Finance Canada
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Valkai Partners with Abbvie to Apply Advanced Ai Across Targeted Areas of Clinical Development - marketscreener.com
Defensive Dividends: 3 Companies Investors Can Rely On - TradingView
AbbVie (NYSE:ABBV) Wins Juvmo Approval for Parkinson's Disease - kalkinemedia.com
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - TradingView
AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says - Yahoo Finance
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Yahoo Finance
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development - Investing News Network
UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium - marketscreener.com
AbbVie partners with Valkai to boost AI in clin... - Pluang
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium - Yahoo Finance
Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's? - Yahoo Finance
FDA Approves AbbVie's Juvmo for Parkinson Disease - Drug Topics
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? - Yahoo Finance
AbbVie gets FDA approval for Parkinson’s disease drug Juvmo - Investing.com
AbbVie's Tavapadon Wins FDA Nod as First D1/D5 Agonist for Parkinson's - finance.biggo.com
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says - Benzinga
AbbVie Wins FDA Approval for Parkinson’s Drug JUVMO - grafa.com
AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start - TIKR.com
AbbVie Receives FDA Approval for Parkinson’s Disease Drug Juvmo - Yahoo Finance
AbbVie (ABBV) Gains FDA Approval for Juvmo, Bolstering Parkinson's Portfolio - GuruFocus
U.S. FDA Approves AbbVie's JUVMO for Parkinson's Disease - Investing News Network
AbbVie Inc. (1ABBV.MI) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie partners with IPO-bound Iambic for AI-led drug discoveries - Crain's Chicago Business
AbbVie Inc Hired Firms, 2019 - OpenSecrets
AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth - Yahoo Finance
AbbVie Inc Hired Firms, 2026 - OpenSecrets
AbbVie Inc Lobbyists, 2026 - OpenSecrets
AbbVie Inc Lobbyists, 2025 - OpenSecrets
Comparative Analysis of AbbVie and Johnson & Johnson in a Shifting Market - Intellectia AI
AbbVie Says Botox Exempt From Medicare Price Negotiations - law360.com
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie’s drug for Parkinson’s disease - WTAQ
Investment Outlook Comparison: AbbVie vs. Pfizer - Intellectia AI
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO - Reuters
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade - 24/7 Wall St.
Allergan Aesthetics - WCIV
ADARx Pharmaceuticals raises $446 million in upsized IPO - qz.com
0.34%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):